Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study

Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease. The management of SHPT commonly involves vitamin D, either calcitriol or newer analogs (paricalcitol or doxercalciferol), along with dietary phosphorus restriction and phosphate binding agents. Published reports...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Kidney international 2010-08, Vol.78 (117), p.S33-S36
Hauptverfasser:	Mittman, Neal, Desiraju, Brinda, Meyer, Kevin B., Chattopadhyay, Jyoti, Avram, Morrell M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Calcinosis - chemically induced calcitriol Calcitriol - adverse effects Calcitriol - therapeutic use Calcium - blood Cross-Over Studies Ergocalciferols - therapeutic use Female hemodialysis Humans Hyperparathyroidism, Secondary - drug therapy Hyperparathyroidism, Secondary - etiology Kidney Failure, Chronic - complications Male Middle Aged paricalcitol Renal Dialysis - adverse effects Retrospective Studies secondary hyperparathyroidism vitamin D
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!